Available therapies for patients with lung cancer are associated with a number of significant toxicities that must be effectively managed by oncologists.
Only about 5% of patients with cancer are recruited into oncology clinical trials, raising a concern that unless this improves, progress in the development new treatments for cancer may be delayed.
The definition of liquid biopsy has expanded to include the collection of cfDNA, along with various species of cell-free RNA and exosomes, all of which are capable of providing information on the disease status of cancer patients.
Early detection in lung cancer is strongly linked to better survival. In a landmark decision the CMS recently approved national coverage for lung cancer screening with LDCT for high-risk smokers.
Benjamin P. Levy, MD, director of thoracic medical oncology, Mount Sinai Health System, discusses maintenance therapies for patients with non-small cell lung cancer.
Roman Perez-Soler, MD, chairman and chief, department of medical oncology, Montefiore Medical Center, deputy director, Albert Einstein Cancer Center, discusses the challenges oncologists still face in lung cancer.
Maria E. Arcila, MD, acting director, Diagnostic Molecular Pathology Laboratory, Memorial Sloan Kettering Cancer Center, discusses diagnostic platforms for lung cancer.
JTT Articles
Management of Hepatocellular Cancer
BioT3 Integrates Diagnosis With Actionable Biomarkers in Metastatic Cancer
External Resources

MJH Associates
Pharmacy Times
Specialty Pharmacy Times
Physicians' Education Resource
Internal Resources

Targeted Communications
Connect With Us:

About Us
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright TargetedOnc 2015
Intellisphere, LLC. All Rights Reserved.